ERBB2 and breast carcinoma: Hormone-targeted therapies and the development of more advanced inhibitors show efficacy in treating breast cancers positive for estrogen (ER) and progesterone receptors (PR), as well as those that display the human epithelial growth factor-2 (HER2/neu) amplification.